BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 35486263)

  • 1. Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications.
    Sofi S; Mehraj U; Qayoom H; Aisha S; Asdaq SMB; Almilaibary A; Mir MA
    Med Oncol; 2022 Apr; 39(6):106. PubMed ID: 35486263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
    Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
    Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
    Węsierska-Gądek J; Kramer MP
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression pattern and prognostic significance of CDKs in breast cancer: An integrated bioinformatic study.
    Mehraj U; Sofi S; Alshehri B; Mir MA
    Cancer Biomark; 2022; 34(3):505-519. PubMed ID: 35491766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
    Santamaria D; Ortega S
    Front Biosci; 2006 Jan; 11():1164-88. PubMed ID: 16146805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
    Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
    Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
    Akin S; Babacan T; Sarici F; Altundag K
    J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in neuro-oncology: the cell cycle--a review.
    Dirks PB; Rutka JT
    Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
    Susanti NMP; Tjahjono DH
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of small molecule degraders for modulating cell cycle.
    Wang L; Yang Z; Li G; Liu Y; Ai C; Rao Y
    Front Med; 2023 Oct; 17(5):823-854. PubMed ID: 37935945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.
    Zabihi M; Lotfi R; Yousefi AM; Bashash D
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1585-1606. PubMed ID: 35781526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
    Di Sante G; Pagé J; Jiao X; Nawab O; Cristofanilli M; Skordalakes E; Pestell RG
    Expert Rev Anticancer Ther; 2019 Jul; 19(7):569-587. PubMed ID: 31219365
    [No Abstract]   [Full Text] [Related]  

  • 19. Cell Cycle Regulation in Treatment of Breast Cancer.
    Cai Z; Liu Q
    Adv Exp Med Biol; 2017; 1026():251-270. PubMed ID: 29282688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA
    Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.